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ABSTRACT
Compounds 18F-fluorodeoxyglucose (18FDG) and 11C-methionine (11C-MET) are radiodiagnostics frequently used in clinical Positron 
Emission Tomography (PET) as well in preclinical studies of various pathologies. The present study was focused on the comparison 
of biodistribution of both radiotracers in intact Wistar rats. The animals were scanned by microPET twice. The first scanning was 
done after 11C-MET administration, the second scan followed 5–7 days later using 18FDG. The radiotracers were injected into the tail 
vein of animals in isoflurane anesthesia. After a redistribution period, whole body scans were obtained using eXplore Vista SrT GE 
tomograph. Accumulation of the drugs in tissues was expressed in relative values (% ID/g) in selected regions of interest. As arbitrary 
reference tissue for drug accumulation, the sternoclavicular area was used. 18C-MET was found remarkably cumulating especially in 
the liver, spleen and distal part of the gastrointestinal tract. The compound was accumulated in the liver 6.9 ± 0.92 (mean ± SEM) 
times more intensively than in the reference tissue. The respective value for spleen and cecum/colon was 5.62 ± 0.81 and 3.56 ± 0.14 
times. Accumulation of 11C-MET in other body parts including the brain and heart was very low and was apparently equal to the 
arbitrary tissue (0.13 ± 0.01% ID/g). In the same animals 18FDG (biontFDG) was remarkably cumulated especially in Harderian glands 
compared to arbitrary tissue background (11.02 ± 1.00 times), heart (7.52 ± 1.70 times), brain (6.14 ± 0.37 times), and colon (5.68 ± 0.31 
times). 18FDG accumulation in the liver, spleen and other organs was apparently not different from that found in the background (0.14 
± 0.02% ID/g). The data obtained may serve as reference values in further microPET preclinical studies with 11C-MET and 18FDG under 
the given conditions. 
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methylation, polyamine generation, transsulfuration 
(Finkelstein & Martin, 1984). However, acute accumula-
tion of 11C-MET in tissues is linked mostly to the rate of 
proteosynthesis (Ishiwata et al., 1988; Fischman et al., 
1998). Besides their use in clinical practice both drugs may 
be also used in preclinical studies focusing on monitoring 
various body functions. However, direct comparison of 
body distribution of the two compounds in the normal 
rat is not available in the literature. Hence, the aim of the 
study was to compare whole body distribution of 11C-
MET and 18FDG after IV administration to intact rats. 
Methods
Male Wistar rats (n=4) weighing 192–217 g were used in 
the study. The animals were kept under standard condi-
tions. They were deprived of food with free access to water 
12 hours prior to experiment. 11C-MET and 18FDG were 
synthesized in house by Cyclone 18/9 cyclotron. 
Rats were anesthetized with isoflurane/oxygen mixture 
(5% induction and 1.5% for maintenance) and 11C-MET 
Introduction
Positron emission tomography is used as valuable diag-
nostic technique in numerous pathologies (Phelps 2000, 
2004). 18F-flurodeoxyglucose (18FDG) and 11C-methionine 
(11C-MET) are radiodiagnostics frequently used in this 
technique. They enter metabolic processes at different 
sites, hence their body distribution as well as affinities 
to different tissues are also different. 18FDG easily enters 
cells by the activity of glucose pumps along with glucose. 
Accumulation of this compound in tissues is considered 
to be a measure of energetic metabolism in cells (Wahl, 
1996; Pauwels et al., 1998; Chen & Dehdashti, 2005). 
Methionine is transported into cells by a complex system 
of transporters (Singhal et al., 2008). It participates in 
several metabolic pathways, mainly in proteosynthesis, 
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with activity of approximately 50 MBq in 0.05–0.5 ml of 
buffered saline was injected into the tail vein. After 15 
min of tracer distribution in the body, the animals were 
placed in the prone position (with head first) on the 
thermostatically heated bed of the microPET scanner 
(eXplore VISTA SrT GE) and scanning started. As field of 
view (FOV) of the scanner is 20 mm in axial direction, for 
whole body image the animals were scanned in sequence 
of 8–10 horizontally moved bed positions, depending 
on the size of the rat. Each bed position was scanned for 
10 minutes, thus scanning time was 80 to 100 minutes. 
Activities measured at different time intervals were 
automatically corrected by the scanner for radionuclide 
decay. After five to seven days, the whole procedure was 
repeated with 18FDG IV injected, allowing 60 min for the 
distribution of the tracer in the body before measurement. 
The shorter distribution time used with 11C-MET 
compared to that with 18FDG was necessitated by shorter 
decay with half-time in 11C than 18F (t1/2 = 20.4 and 109.8 
min, respectively).
After radioactivity of administered 18FDG decreased 
sufficiently (>10 half-times), the animals were sacrificed 
and autopsy was carried out, focused on position of indi-
vidual organs within the body.
Analysis of PET data
Images were reconstructed and analyzed by eXplore 
VISTA 3.1 Analysis & Visualisation software. For image 
reconstruction 3D FORE/2D OSEM algorithms were 
used. Regions of interest (ROI) with evident tracer accu-
mulation were identified and manually marked in the 
area of the brain, heart, liver, spleen, kidneys, colon, and 
Harderian glands. Sternoclavicular area was considered 
to be arbitrary tissue background. The ROI dimensions 
were at least 2.5 times resolution of the camera which 
is 1.5 mm. Relative accumulation of the radioactivity in 
particular ROI was expressed as % ID/g. 
Statistical analysis was done in GraphPad Prism 
software. The data are expressed as means with their 
standard errors (SEM). 
Calculations
Distribution of the radiodiagnostics administered was 
expressed by percentage of the radioactivity administered 
to the animal relative to one gram of the tissue selected 
( % D / g). The variable was calculated in each selected 
region of interest (ROI) according to Gambhir (2004), 
Shimoji et al. (2004), Aliaga et al. (2007) by the formula:
/ (ρ [g/cm3])
TD [kBq]
c[kBq/cm3]
%ID/g = 100 ×     (1)
where c is radionuclide concentration in ROI expressed 
by the formula (2), ρ is tissue density (i.e. ~1 g/cm3), TD is 
total injected dose corrected to scan onset time.
       (2)
cps in a animal ROI [cps]
ROI volume in image [cm3]
c = C ×
where C is calibration factor calculated using calibra-
tion phantom (cylinder).
cps in a  ROI 
ROI volume in image 
radionuclide concentration in cylinder [kBq/cm3]
C =
[cps/cm3]
      (3)
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Figure 1. Accummulation of the radiotracers in the rat. A – 11C-MET, coronal view, B and C – 18FDG, coronal and sagittal 
view, respectively.54
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Results
Accumulation of 11C-MET and 18FDG following IV 
administration was measured in whole body of animals 
after chosen distribution periods. Static measurement 
lasting 10 min for each 20 mm section of the body was 
used. In Figure 1 an example of body scans of one of the 
animals is presented after IV administration of 11C-MET 
(panel A) and 18FGD (panels B and C). Identification of 
the organs assessed was facilitated using 3D reconstruc-
tion of the scans with rotation of the scanned objects as 
well as by anatomical dissection made post mortem. 
Accumulation of the compounds expressed in rela-
tive values as % ID/g in selected organs are presented in 
Figure 2. The highest accumulation of 11C-MET was 
observed in the liver followed by the spleen and colon. 
Compared to that in the arbitrary reference area, accu-
mulation ranged from >6 times higher in the liver to 3.5 
times higher in the colon (Table 1). The compound was 
apparently not accumulating in the brain in the given 
time period. 
18FDG revealed a different accumulation profile and 
intensity than 11C-MET (Figure 2). It was accumulated 
most markedly in Harderian glands with as high as 11 
times more intensively captured here than in the refer-
ence region (Table 2). Accumulation in the kidney, heart, 
brain, and colon was gradually lower, being in the colon 
still more than 5.6 times higher than in the reference 
area. Data on 18FDG accumulation in the kidney obtained 
in the present study are not reliable because of the low 
number of measurements (n=3) and their high variability. 
Consequently, any statement on 18FDG accumulation in 
this tissue has only limited reliability. 
Discussion
The present study revealed different profiles of body 
distribution of 11C-MET and 18FDG in the intact rat. 
Especially a comparatively high uptake of 11C-MET was 
observed in the liver, spleen, and colon and an apparently 
very low uptake occurred in the brain and other organs. 
On the other hand, a high uptake of 18FDG was found in 
the Harderian glands, heart, brain and colon.
Several authors studied methionine body distribution 
in various objects. Edwards et al. (1963) analyzed the fate 
of 14C-L-methionine in numerous tissues 30 min after its 
administration to Wistar rats. They observed the follow-
ing profile – pancreas > liver > bone marrow > kidneys > 
lungs. They concluded that the liver plays an important 
r o l e  i n  t h e  m e t a b o l i s m  o f  m e t h i o n i n e .  A c c o r d i n g l y ,  
Kubota et al. (1984) found a higher accumulation of 11C-
MET in the pancreas than in the liver in the rat with hepa-
toma AH109A. Amano et al. (1998) studied accumulation 
of 11C-L-methionine in nude mice with human breast 
carcinoma MCF-7. The most remarkable uptake of the 
tracer was found in the liver. The uptake was decreasing 
in the following order: liver > kidney > spleen > stomach > 
blood > skeletal muscle. Cook et al. (1999) in their review 
article about clinical PET applications and investigations 
indicated low uptake in the central nervous system and 
high uptake in the abdomen and pelvis. They described 
high liver activity, variable accumulation in bowel and 
bladder and low activity in the kidney.
Our observations of high accumulation of 11C-MET in 
the liver and spleen are in agreement with the above find-
ings. However, no evident uptake in kidneys and lungs was 
observed, unlike that found by Edwards et al. (1963) and 
Amano et al. (1998). The differences might be related to 
different ways of administration of the radiodiagnostics, 
by interspecies differences, and/or by different health 
status of the animals. Moreover, microPET itself without 
corresponding imaging techniques (MRI, CT, autora-
diography) did not allow to draw reliable conclusions of 
Table 1. Ratio of the % ID/g values in some organs to that in the arbi-
trary background following 11C-MET IV administration (n=4). 
organ
%ID/g in organ/background
average SEM animal 1 animal 2 animal 3 animal 4
liver 5.87 5.27 9.00 5.00 6.29 0.92
spleen 4.67 4.36 7.92 5.53 5.62 0.81
colon 3.93 3.27 3.50 3.53 3.56 0.14
brain 0.80 0.73 1.33 1.07 0.98 0.14
Table 2. Ratio of the % ID/g values in some organs to that in the arbi-
trary background following 18FDG IV administration (n=3). 
organ
% ID/g in organ/background  
average SEM animal 1 animal 2 animal 3
Hard. glands 9.08 11.58 12.41 11.02 1.00
kidneys 1.00 30.33 1.00 10.78 9.78
heart 4.83 10.67 7.06 7.52 1.70
brain 5.42 6.42 6.59 6.14 0.37
colon 6.17 5.75 5.12 5.68 0.31
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Figure 2. Accumulation of 11C-MET and 18FDG administered IV 
in various organs expressed as percentage of the injected dose 
per gram of the tissue (% ID/g). The sternoclavicular area was 
selected as abitrary reference background. Means with SEM are 
shown.55
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11C-MET accumulation in smaller organs in the present 
study.
Low basal uptake of 11C-MET observed in the brain and 
heart allows to expect facilitated detection of pathologies 
causing enhanced tissue uptake of methionine in these 
organs induced by increased proteosynthesis (tumors, 
inflammation, tissue reparation processes, etc.).
Data on body distribution of 18FDG were presented 
by numerous authors. Among them Cook et al. (1999) 
summarized normal distribution of 18FDG in men. The 
highest uptake was typically in the central nervous sys-
tem, variable uptake was found in the cardiovascular and 
gastrointestinal system and low grade accumulation was 
in the liver, spleen, skeletal muscle and lung. Yamaguchi et 
al. (1999) described distribution of 18FDG in men after PO 
administration. They observed organ accumulation in the 
following order: intestine > brain > liver > stomach. The 
high accumulation in the intestine was not surprising due 
to the way of administration of the tracer. In PET Protocol 
for Oncological Diagnostics of the Munich University 
(Anonym, 2000), the highest 18FDG accumulation was 
found in the brain followed by that in the liver and 
mediastinum. Enhanced 18FDG uptake was also found 
in malignant tumors. Tan & Ong (2004) reported 18FDG 
uptake in men: cerebellum > myocardium > tonsiles > 
liver > spleen > stomach > rectum.
Our findings correspond comparatively well with the 
observations of the above authors. High uptake of 18FDG 
in the heart and brain are in accordance with the well 
known high rate of energetic metabolism in these organs. 
Remarkably high accumulation of 18FDG in Harderian 
glands found in the present study was observed also by 
Fukuyama et al. (1998), however this phenomenon has not 
been fully explained yet. 
The different profiles of uptake of 11C-MET and 18FDG 
found in the present study may undoubtedly be linked to 
their different metabolism pathways in different organs. 
This difference might be advantageous in diagnosis of 
suspected neoplastic processes, brain ischemia, hypoxia, 
etc. Particularly the low basal accumulation of 11C-MET 
might allow to identify any pathology in this tissue com-
prising increase of proteosynthesis.
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